Drugs / pTVG-HP
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07090148 | Mar 2026 → Oct 2030 expected | metastatic prostate carcinoma | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT00582140 | Mar 2005 → Aug 2008 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02499835 | Jul 2015 → Aug 2021 | hormone-resistant prostate carcinoma, malignant soft tissue neoplasm, metastatic carcinoma in the bone, metastatic prostate carcinoma +1 | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04090528 | Oct 2019 → Nov 2024 overdue | castration-resistant prostate carcinoma, metastatic malignant neoplasm | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03600350 | Sep 2018 → Nov 2022 overdue | prostate cancer | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01706458 | May 2013 → Jun 2017 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT01341652 | May 2011 → Jun 2020 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00849121 | Mar 2009 → Feb 2014 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pTVG-hp | “PURPOSE: We previously reported the safety and immunologic effects of a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid phosphatase (PAP) in patients with recurrent,...” PMID 31644357 ↗ Oct 20198“Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer” PMID 39208856 ↗ Aug 2024 “a DNA vaccine encoding PAP (pTVG-HP) could elicit PAP-specific, Th1-biased T cells” PMID 29534736 ↗ Mar 2018 |
| Known as | MVI-816 | “PURPOSE: We previously reported the safety and immunologic effects of a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid phosphatase (PAP) in patients with recurrent,...” PMID 31644357 ↗ Oct 20191“a DNA vaccine encoding prostatic acid phosphatase (MVI-816, pTVG-HP), given over 12 weeks concurrently or sequentially with pembrolizumab” PMID 35277461 ↗ Mar 2022 |
| Modality | Vaccine | “a DNA vaccine encoding prostatic acid phosphatase (PAP)” PMID 28716080 ↗ Jul 2017 |
| Route | Other | “pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until...” NCT00849121 ↗ |